CLINICAL_TRIALS
trial_result
· 2011-06-07
Clinical Trial Update: Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients [Phase 2]
Summary
This Phase 2 study evaluated the efficacy and safety of three doses of BI1356 (linagliptin) in patients with type 2 diabetes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2011-06-07